🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 20 of 28

  1. OMP-54F28

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  2. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

  3. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  4. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  5. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  6. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  7. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  8. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  9. ONO-4578

    Ono Pharmaceutical Co.,

    Metastatic Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  10. OP-3136

    Olema Pharmaceuticals

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

  11. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

  12. OPB-51602

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 1 small molecule terminated

    1 trial

  13. ORIC-101

    Topiloric/Uriadec

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  14. ORIC-101

    Topiloric/Uriadec

    Prostatic Neoplasms

    phase 1 small molecule terminated

    1 trial

  15. ORIC-114 Dose 1 + amivantamab

    Topiloric/Uriadec

    Solid Tumors

    phase 1 small molecule active

    1 trial

  16. ORIC-944

    Topiloric/Uriadec

    Metastatic Prostate Cancer

    phase 1 small molecule active

    1 trial

  17. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkins Lymphoma (B-NHL)

    phase 1 small molecule active

    1 trial

  18. Odronextamab multiple dose levels

    Regeneron UK Limited

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  19. Olaparib tablets, 150 mg

    Sandoz Pty Ltd

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  20. Olutasidenib Investigational Agent Administration

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  21. Olverembatinib, APG-2575, Dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 small molecule active

    1 trial

  22. Omacetaxine

    Teva Pharma GmbH

    Hematologic Tumors

    phase 1 small molecule completed

    1 trial

  23. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  24. Oncolytic Virus SDJ001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 small molecule active

    1 trial

  25. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  26. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  27. Osimertinib

    PUMA BIOTECHNOLOGY, INC.

    Lung Cancer Metastatic

    phase 1 small molecule active

    1 trial

  28. PAN-301-1

    Sensei Biotherapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

  29. PARP inhibitor BMN-673

    BioMarin Pharmaceutical Australia Pty Ltd

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  30. PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

  31. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  32. PD-L1/IDO Peptide Vaccine

    IO Biotech

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

  33. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  34. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  35. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Solid Tumor

    phase 1 small molecule completed

    2 trials

  36. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Cholangiocarcinoma Non-resectable

    phase 1 small molecule terminated

    1 trial

  37. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  38. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  39. PH-762

    Phio Pharmaceuticals

    Squamous Cell Carcinoma of the Skin

    phase 1 small molecule active

    1 trial

  40. PIC1 Injection

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  41. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  42. PLN-101095

    PLIANT THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  43. PRG2302

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  44. PRT1419

    Prelude Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial

  45. PRT1419

    Prelude Therapeutics Inc

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  46. PRT2527

    Prelude Therapeutics Inc

    Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial

  47. PRT2527

    Prelude Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial

  48. PRT3645

    Prelude Therapeutics Inc

    Breast Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.